Aqueous flare is a major risk factor for PVR redetachment

Article

Preoperative aqueous flare is a significant risk factor for proliferative vitreoretinopathy (PVR) redetachment in patients with rhegmatogenous retinal detachment.

Preoperative aqueous flare is a significant risk factor for proliferative vitreoretinopathy (PVR) redetachment in patients with rhegmatogenous retinal detachment, according to a paper published in Retina.

Dr Sabine Schröder et al., Department of Vitreo-Retinal Surgery and Institute of Medical Statistics, Informatics and Epidemiology, Center of Ophthalmology, University of Cologne, Germany, preoperatively measured the aqueous flare of 116 consecutive patients with retinal detachment.

A laser flare-cell meter was used to conduct aqueous flare measurements. The control group consisted of 74 healthy eyes of 41 healthy age-matched patients. Six month postoperatively, patients were re-evaluated to determine whether surgery should be repeated due to PVR redetachment.

Higher flare values were found in eyes with retinal detachment that had developed PVR redetachment, compared to eyes with uneventful retinal detachment. All eyes with PVR redetachment had a flare value of over 10.8 photon counts per millisecond. In eyes with flare values of over 15 photon counts per millisecond the chances of PVR redetachment was found to increase 16 times.

The breakdown of the blood-ocular barrier, as determined by aqueous flare, presented as a major PVR redetachment risk factor. It was also found that the laser flare-cell meter is a non-invasive, efficient and safe device that enables the prediction of preoperative PVR redetachment risk.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.